Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Lee (Chuncheon, Republic of Korea). Clinical Efficacy and Cost-Effectiveness Analysis of Cefepime or Piperacillin/tazobactam both with Ciprofloxacin in MICU Patients with Severe Pneumonia. 2922

Member's Comments

No comment yet.

Related content which might interest you: Twenty-year Trend in Mortality among Hospitalized Patients with Pneumococcal Community-Acquired Pneumonia Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Meta-analysis of Acute Coronary Syndrome in Patients with Community-Acquired Pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Psychiatric Complications in Patients Receiving Treatment for Multi-Drug Resistant Tuberculosis Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Effect of Oral Chlorhexidine in Preventing Hospital-Acquired Pneumonia among non-intubated patients in the Philippines Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Clinical Features Associated with Linezolid Resistance Among Multidrug Resistant Tuberculosis Patients at a Tertiary Care Hospital in Mumbai, India Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis Source: Virtual Congress 2021 – Pneumonia Year: 2021 Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Viral Sepsis in Adults with Community-Acquired Pneumonia Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community Source: Virtual Congress 2020 – Clinical challenges in pneumonia Year: 2020 Efficacy of Ceftolozane/Tazobactam in Comparison with Piperacillin/Tazobactam in Severe Pseudomonas aeruginosa Pneumonia Swine Model Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Assessment of Efficacy Omalizumab Retreatment in Patients With Severe Asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Time to Blood Culture Positivity as a Predictor of Clinical Outcomes and Severity in Adults with Bacteremic Pneumococcal Pneumonia Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Thirty-Day Readmission Among Patients With Non-Ventilator Hospital Acquired Pneumonia and Effects on Outcomes. Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 SOFA (Sequential Organ Failure Assessment) Score As A Predictor Of Moartality In Ventilated Patients With Multi-drug Resistant Bacteremia Source: Virtual Congress 2020 – Novel findings in intensive care unit medicine: part 1 Year: 2020 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Risk of Haemophilus Influenzae Infection in Patients with Chronic Obstructive Pulmonary Disease Using Inhaled Corticosteroids: A Cohort Study of 23,789 Outpatients. Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021